Research ExplorerPublicationsAllogeneic stem cell transplantation following relapse post ...

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT

Standard

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. / Christopeit, Maximilian; Labopin, Myriam; Gorin, Norbert-Claude; Saraceni, Francesco; Passweg, Jakob; Forcade, Edouard; Maertens, Johan; Van Lint, Maria Teresa; Bosi, Alberto; Niederwieser, Dietger; Ehninger, Gerhard; Polge, Emmanuelle; Mohty, Mohamad; Nagler, Arnon.

In: AM J HEMATOL, Vol. 93, No. 12, 12.2018, p. 1532-1542.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Christopeit, M, Labopin, M, Gorin, N-C, Saraceni, F, Passweg, J, Forcade, E, Maertens, J, Van Lint, MT, Bosi, A, Niederwieser, D, Ehninger, G, Polge, E, Mohty, M & Nagler, A 2018, 'Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT', AM J HEMATOL, vol. 93, no. 12, pp. 1532-1542. https://doi.org/10.1002/ajh.25285

APA

Christopeit, M., Labopin, M., Gorin, N-C., Saraceni, F., Passweg, J., Forcade, E., Maertens, J., Van Lint, M. T., Bosi, A., Niederwieser, D., Ehninger, G., Polge, E., Mohty, M., & Nagler, A. (2018). Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. AM J HEMATOL, 93(12), 1532-1542. https://doi.org/10.1002/ajh.25285

Vancouver

Christopeit M, Labopin M, Gorin N-C, Saraceni F, Passweg J, Forcade E et al. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. AM J HEMATOL. 2018 Dec;93(12):1532-1542. https://doi.org/10.1002/ajh.25285

Bibtex

@article{ed69233591864685aa5074f9dc7f9a39,
title = "Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT",
abstract = "Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38.8], and nonrelapse mortality (NRM) 33.7% [95%CI 29.6-37.9]. RI was higher in patients transplanted in relapse in comparison to those transplanted in CR2 (HR 1.76, P = .004) and in patients who relapsed later after ASCT (HR 0.97 per month, P < 10-3 ), both translating into better LFS/ OS. Relapse was also lower in patients undergoing allogeneic stem cell transplantation (allo-HSCT) from an unrelated donor (UD) in comparison to those transplanted from a matched sibling donor (MSD) (HR 0.49, P < 10-3 ). NRM was increased in patients who received total body irradiation (TBI) pre-ASCT (HR 2.43; P < 10-4), translating into worse LFS/OS. LFS/OS did not differ between patients allotransplanted with reduced intensity (RIC) or myeloablative (MAC) conditioning. In conclusion, one third of adult patients with AML relapsing post ASCT can be rescued with allo-HSCT, with better LFS/OS in patients who relapsed later post ASCT, those transplanted in CR2 and those who had not received TBI pre-ASCT.",
keywords = "Journal Article",
author = "Maximilian Christopeit and Myriam Labopin and Norbert-Claude Gorin and Francesco Saraceni and Jakob Passweg and Edouard Forcade and Johan Maertens and {Van Lint}, {Maria Teresa} and Alberto Bosi and Dietger Niederwieser and Gerhard Ehninger and Emmanuelle Polge and Mohamad Mohty and Arnon Nagler",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = dec,
doi = "10.1002/ajh.25285",
language = "English",
volume = "93",
pages = "1532--1542",
journal = "AM J HEMATOL",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT

AU - Christopeit, Maximilian

AU - Labopin, Myriam

AU - Gorin, Norbert-Claude

AU - Saraceni, Francesco

AU - Passweg, Jakob

AU - Forcade, Edouard

AU - Maertens, Johan

AU - Van Lint, Maria Teresa

AU - Bosi, Alberto

AU - Niederwieser, Dietger

AU - Ehninger, Gerhard

AU - Polge, Emmanuelle

AU - Mohty, Mohamad

AU - Nagler, Arnon

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018/12

Y1 - 2018/12

N2 - Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38.8], and nonrelapse mortality (NRM) 33.7% [95%CI 29.6-37.9]. RI was higher in patients transplanted in relapse in comparison to those transplanted in CR2 (HR 1.76, P = .004) and in patients who relapsed later after ASCT (HR 0.97 per month, P < 10-3 ), both translating into better LFS/ OS. Relapse was also lower in patients undergoing allogeneic stem cell transplantation (allo-HSCT) from an unrelated donor (UD) in comparison to those transplanted from a matched sibling donor (MSD) (HR 0.49, P < 10-3 ). NRM was increased in patients who received total body irradiation (TBI) pre-ASCT (HR 2.43; P < 10-4), translating into worse LFS/OS. LFS/OS did not differ between patients allotransplanted with reduced intensity (RIC) or myeloablative (MAC) conditioning. In conclusion, one third of adult patients with AML relapsing post ASCT can be rescued with allo-HSCT, with better LFS/OS in patients who relapsed later post ASCT, those transplanted in CR2 and those who had not received TBI pre-ASCT.

AB - Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38.8], and nonrelapse mortality (NRM) 33.7% [95%CI 29.6-37.9]. RI was higher in patients transplanted in relapse in comparison to those transplanted in CR2 (HR 1.76, P = .004) and in patients who relapsed later after ASCT (HR 0.97 per month, P < 10-3 ), both translating into better LFS/ OS. Relapse was also lower in patients undergoing allogeneic stem cell transplantation (allo-HSCT) from an unrelated donor (UD) in comparison to those transplanted from a matched sibling donor (MSD) (HR 0.49, P < 10-3 ). NRM was increased in patients who received total body irradiation (TBI) pre-ASCT (HR 2.43; P < 10-4), translating into worse LFS/OS. LFS/OS did not differ between patients allotransplanted with reduced intensity (RIC) or myeloablative (MAC) conditioning. In conclusion, one third of adult patients with AML relapsing post ASCT can be rescued with allo-HSCT, with better LFS/OS in patients who relapsed later post ASCT, those transplanted in CR2 and those who had not received TBI pre-ASCT.

KW - Journal Article

U2 - 10.1002/ajh.25285

DO - 10.1002/ajh.25285

M3 - SCORING: Journal article

C2 - 30218444

VL - 93

SP - 1532

EP - 1542

JO - AM J HEMATOL

JF - AM J HEMATOL

SN - 0361-8609

IS - 12

ER -